EP2313054A2 - Mousse de soins cutanés - Google Patents

Mousse de soins cutanés

Info

Publication number
EP2313054A2
EP2313054A2 EP09772048A EP09772048A EP2313054A2 EP 2313054 A2 EP2313054 A2 EP 2313054A2 EP 09772048 A EP09772048 A EP 09772048A EP 09772048 A EP09772048 A EP 09772048A EP 2313054 A2 EP2313054 A2 EP 2313054A2
Authority
EP
European Patent Office
Prior art keywords
formulation according
pharmaceutical
care
panthenol
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09772048A
Other languages
German (de)
English (en)
Inventor
Thomas Neubourg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neubourg Skin Care GmbH and Co KG
Original Assignee
Neubourg Skin Care GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neubourg Skin Care GmbH and Co KG filed Critical Neubourg Skin Care GmbH and Co KG
Publication of EP2313054A2 publication Critical patent/EP2313054A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns

Definitions

  • the invention relates to a foam skin care cream that can be used for wound care as well as for the care, reassurance and prophylactic treatment of stressed skin.
  • the use is topical as needed, and is particularly, but not exclusively, indicated in the area of the feet, in the prevention and treatment of mycoses, especially in athlete's foot, and in atopic dermatitis.
  • the skin is the functionally most versatile organ of the human organism and requires a correspondingly versatile care. Wound healing itself is a natural biological process.
  • the foam skin care cream according to the invention is suitable for wound care in order to prevent complications or infections and delays in wound healing and to optimally shape the cosmetic result of the healing.
  • Typical symptoms include dry skin with fissures and rhagades and concomitant symptoms such as inflammation, ulcers etc.
  • German patent application 103 40 277 relates to a personal care product with metallic silver.
  • Japanese application 1994-62 85 131 discloses a bath additive for the treatment of atopic dermatitis consisting of a porous ceramic
  • Carrier material with silver, copper, zinc or one of these combinations is Carrier material with silver, copper, zinc or one of these combinations.
  • Japanese application 2002-22 63 83 describes a topical formulation for the treatment of atopic dermatitis containing, inter alia, 0.1 to 10% by weight of an antimicrobial ceramic material of silver, tricalcium phosphate, zinc oxide and silicone dioxides.
  • German patent application 103 42 258 relates to an antimicrobial, topical preparation with nanoscale elemental silver in a carrier pasty consistency of ultrafine barium sulfate for the treatment of atopic dermatitis.
  • European patent application 1 685 824 relates to a cosmetic formulation for the treatment of inter alia atopic dermatitis which consists of elemental silver, an electrolyte and hydrophobic particles.
  • the nature and composition of the silver preparations in the previously mentioned disclosures is different from microsilicone as used in the present invention. This comprises highly porous silver with an average particle size of 10 ⁇ m and a surface area of up to 5 m 2 / g and is available under the name "MicroSilver BG TM" from the company BioEpiderm GmbH in Nuremberg.
  • German patent application 10 2005-008299 discloses the use of colloidal, highly porous silver in a cosmetic and / or dermatological formulation for the care, soothing, prophylactic treatment and / or treatment of stressed, chapped, reddened and / or itchy skin to aid one Wound healing, as an antiseptic, for the antimicrobial and / or antifungal treatment of the skin and / or in atopic dermatitis.
  • Patent EP 1303283 discloses the use of nanocrystalline silver in a topical formulation for the treatment of hyperproliferative skin diseases.
  • German utility model applications 20 2006 014 258.4, 20 2006 004 676.3 and 202 06 983.4 were - as the present application - by Neubourg Skin Care GmbH & CO. KG and describe urea (urea) -containing foam skin care creams and skin care products.
  • clotrimazole as a broad-spectrum antifungal has long been known.
  • the active ingredient was developed by Bayer AG in the late 1960s. Most forms of preparation are now among the non-prescription drugs and are available as generic from different manufacturers. - A -
  • Panthenol also called pantothenol
  • Panthenol has long been used to help heal the skin. Panthenol increases the moisture retention capacity of the skin, has nourishing properties and improves the elasticity of the skin. It supports the regeneration of the skin cells and thus contributes to the regeneration of the latter.
  • panthenol also has antipruritic and anti-inflammatory properties. Panthenol is used topically and has been known since 1944 under the trade name Bepanthen®.
  • Panthenol also called dexpanthenol, D (+) - pantothenyl alcohol or D (+) - pantothenol, is biologically active.
  • D-panthenol is preferably used according to the invention, but alternatively L-panthenol or a mixture of different enantiomers may also be used.
  • Madecassoside is a concentrated extract of Centella asiatica and has long been known for its effectiveness in wound healing.
  • avocado oil is used in the cosmetics and pharmaceutical industries.
  • the object of the invention is furthermore to provide a foam cream which is suitable for the prophylaxis and therapy of mycoses, athlete's foot and the like. It is also an object of the invention to provide a foam cream, which is suitable for the prophylaxis and treatment of atopic dermatitis and similar skin diseases.
  • Foam formulations have the advantage of being easily distributed on the skin.
  • the foamy texture is pleasant and the products usually leave a good skin feeling.
  • the physical structure of the foam has a positive effect on the skin protection function.
  • Foams are complicated physical structures that require special tuning of the foam-forming components. Foams are generally obtained by spraying an emulsion formulation or an aqueous surfactant (stabilizer) solution
  • Foaming formulations according to the invention have a stable two-phase or multi-phase polydisperse structure on application which forms a network structure on the skin comparable to a membrane.
  • Such network structures have the advantage that they form a protective function, for example before contact with water, but allow unimpeded gas exchange with the environment. In such foams, there is virtually no obstruction of Perspiratio insensibiles and no corresponding heat accumulation. Thus, the positive properties of a protective and care function are associated with an unchanged skin respiration.
  • the foam cream according to the invention contains microsilicone and preferably panthenol. It will be advantageous with one or more pharmaceutical and / or combined with cosmetically active additives. It is characterized by particularly advantageous, previously unknown drug combinations. In particular, hitherto the extremely effective combination of natural substances with conventional active ingredients for wound healing was unknown.
  • a preferred embodiment contains microsilver and panthenol natural substances, which are referred to as Madecassoside.
  • the wound-healing effects of panthenol and madecassoide complement each other in combination with microsilver to a previously unknown extent.
  • the formulation with microsilver additionally allows the antimicrobial and / or antifungal treatment of the skin.
  • the highly porous structure of microsilver prevents a toxicologically problematic penetration into deeper skin layers.
  • a particularly preferred embodiment in addition to microsilver, panthenol, madecassosides, also contains urea. Urea causes an increase in the
  • This embodiment is particularly - but not only - suitable for use in the foot area.
  • Madecassoside also evening primrose oil.
  • the wound-healing effect of panthenol and madecassoide is complemented with evening primrose oil to a care product, which is particularly - but not only - suitable for the treatment of atopic dermatitis.
  • Another preferred embodiment contains microsilver, panthenol, clotrimazole and avocado oil.
  • the combination of wound-healing-promoting agents with the antimycotic clotrimazole and microsilver provides a particularly effective formulation for the care of fungus-sensitive skin.
  • the said formulation is particularly suitable for the treatment or prevention of athlete's foot.
  • Foam creams are aerosols which are formed from an emulsion by means of propellant gas by spraying from a suitable container / dosage form.
  • Foam cream formulations therefore generally contain an emulsion and propellant gas.
  • Suitable propellants include a propane-butane mixture which causes the pressurized mixture to form foam bubbles.
  • the formulation contains 5-15% by weight of propane butane as a propellant gas.
  • the propellant is air using an airless dispenser.
  • the foam cream according to the invention for use in the foot area is prepared in a suitable, known per se apparatus.
  • long-chain esters, alcohols and carboxylic acids described in the prior art and one of the common products against excessive perspiration are preferably used.
  • the following recipe belongs to the particularly preferred embodiments of the present invention:
  • the remaining percentages by weight are water. From the recipe 85-95 wt .-% are filled with corresponding to 5-15 wt .-% propane-butane as a propellant gas.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une formulation d'une mousse de soins cutanés, comprenant une émulsion aqueuse et un agent propulseur, caractérisée en ce que l'émulsion contient des microparticules d'argent.
EP09772048A 2008-06-30 2009-05-12 Mousse de soins cutanés Withdrawn EP2313054A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008031023A DE102008031023A1 (de) 2008-06-30 2008-06-30 Schaumhautpflegecreme
PCT/EP2009/003369 WO2010000348A2 (fr) 2008-06-30 2009-05-12 Mousse de soins cutanés

Publications (1)

Publication Number Publication Date
EP2313054A2 true EP2313054A2 (fr) 2011-04-27

Family

ID=40935535

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09772048A Withdrawn EP2313054A2 (fr) 2008-06-30 2009-05-12 Mousse de soins cutanés

Country Status (11)

Country Link
US (1) US20110097281A1 (fr)
EP (1) EP2313054A2 (fr)
JP (1) JP2011526258A (fr)
KR (1) KR20110040869A (fr)
CN (1) CN102076314A (fr)
CA (1) CA2726538A1 (fr)
DE (1) DE102008031023A1 (fr)
MX (1) MX2010013983A (fr)
RU (1) RU2011103256A (fr)
WO (1) WO2010000348A2 (fr)
ZA (1) ZA201008693B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202009016573U1 (de) * 2009-12-08 2010-03-04 Schermuly, Helmut Dermale, antimikrobielle Fußcreme
PL2371350T3 (pl) 2010-03-04 2013-09-30 Neubourg Skin Care Gmbh & Co Kg Preparaty piankowe do leczenia chorób skóry u zwierząt
IT1402786B1 (it) * 2010-11-19 2013-09-18 Fidia Farmaceutici Composizioni farmaceutiche ad attivita' antibatterica e cicatrizzante
EP2641584A1 (fr) * 2012-03-19 2013-09-25 Coty Germany GmbH Composition cosmétique de la peau avec effet apaisant et son utilisation
WO2014157174A1 (fr) * 2013-03-29 2014-10-02 ホーユー株式会社 Composition pour le corps, et agent anti-champignon malassezia
FR3025106B1 (fr) * 2014-08-27 2017-12-08 Dermaconcept Jmc Composition antimicrobienne
US20170000696A1 (en) * 2015-03-24 2017-01-05 The Procter & Gamble Company Methods of applying a high dose of a skin care active to skin with improved sensory benefits to the skin
US20170000711A1 (en) * 2015-03-24 2017-01-05 The Procter & Gamble Company Foam compositions, aerosol products, and methods of using the same to improve sensory benefits to the skin
CN106074264A (zh) * 2016-07-05 2016-11-09 上海相宜本草化妆品股份有限公司 一种添加剂及包含该添加剂的化妆品
CN107802521A (zh) * 2017-12-04 2018-03-16 湖南金昌生物技术有限公司 一种富含山茶籽提取物的免洗型泡沫护肤乳液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023213A1 (fr) 2003-08-29 2005-03-17 Bio-Gate Ag Produit de soin corporel contenant des particules poreuses d'argent
US20080152715A1 (en) * 2006-12-26 2008-06-26 Seoul National Universtiy Industry Foundation Method for preparing nanoparticles comprising vitamin K and poly-isopropyl-butyl methacrylate-acrylic acid copolymer with supercritical fluid using molecular association theory

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06285131A (ja) 1993-04-07 1994-10-11 Asupatsuku Kigyo Kk アトピー性皮膚炎治療材
WO1997029727A1 (fr) 1996-02-19 1997-08-21 Pierre Giroud Porte-cannes
US20040161447A1 (en) * 2000-02-17 2004-08-19 Leonard Paul Liquid foam producing compositions and dispensing system therefor
WO2002009729A2 (fr) 2000-07-27 2002-02-07 Nucryst Pharmaceuticals Corp. Traitement des troubles et maladies cutanes a caractere hyperporliferatif
JP2002226383A (ja) 2001-01-30 2002-08-14 Masashi Fujii 持続性広範囲抗微生物スペクトル皮膚外用剤
DE20206983U1 (de) 2002-05-03 2002-07-18 Allpresan Ges Zum Vertrieb Von Sprühvorrichtung
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
FR2858766B1 (fr) * 2003-08-11 2005-11-11 Oreal Composition cosmetique comprenant des particules metalliques stabilisees, eventuellement enrobees
US20050186151A1 (en) * 2003-08-11 2005-08-25 Franck Giroud Cosmetic composition comprising stabilized and optionally coated metal particles
DE10340276B4 (de) 2003-08-29 2006-11-09 Bio-Gate Bioinnovative Materials Gmbh Körperpflegemittel mit Silber und Zink
DE10342258A1 (de) 2003-09-11 2005-04-07 Josef Peter Prof. Dr.med. Guggenbichler Antimikrobiell wirkendes Präparat zur äußerlichen Anwendung
ZA200507017B (en) * 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
IL166646A0 (en) 2005-01-30 2006-01-15 Or Le Or Ltd A new cosmetic composition
DE102005008299A1 (de) 2005-02-23 2006-12-28 Icb Investment Consulting Beteiligungen Gmbh Universalpflegecreme
DE202006004676U1 (de) 2005-09-28 2007-02-08 Neubourg Skin Care Gmbh & Co. Kg Hautpflegeprodukte
KR20080065641A (ko) * 2005-11-09 2008-07-14 바이엘 컨수머 케어 악티엔게젤샤프트 센텔라 아시아티카로부터의 화합물의 용도
US8858968B2 (en) * 2005-12-05 2014-10-14 L'oreal Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist
WO2009069006A2 (fr) * 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023213A1 (fr) 2003-08-29 2005-03-17 Bio-Gate Ag Produit de soin corporel contenant des particules poreuses d'argent
US20080152715A1 (en) * 2006-12-26 2008-06-26 Seoul National Universtiy Industry Foundation Method for preparing nanoparticles comprising vitamin K and poly-isopropyl-butyl methacrylate-acrylic acid copolymer with supercritical fluid using molecular association theory

Also Published As

Publication number Publication date
WO2010000348A8 (fr) 2010-03-11
MX2010013983A (es) 2011-01-20
CA2726538A1 (fr) 2010-01-07
ZA201008693B (en) 2012-01-25
DE102008031023A1 (de) 2009-12-31
US20110097281A1 (en) 2011-04-28
WO2010000348A3 (fr) 2010-06-10
RU2011103256A (ru) 2012-08-10
JP2011526258A (ja) 2011-10-06
CN102076314A (zh) 2011-05-25
KR20110040869A (ko) 2011-04-20
WO2010000348A2 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
EP2313054A2 (fr) Mousse de soins cutanés
EP2363108B1 (fr) Formulation d'une mousse contenant au moins un triterpénoïde
EP2335675B1 (fr) Formules de mousse sans émulsifiant et stabilisées par polymères
EP1937224A2 (fr) Produits pour le soin de la peau
EP2029089A1 (fr) Émulsion h/e pour le soin de la main
WO2012146576A1 (fr) Concentré d'émulsion huile dans l'eau, procédé de préparation dudit concentré et produit cosmétique pour la peau contenant celui-ci
DE4438588A1 (de) Gegen unreine Haut, leichte Formen der Akne sowie Propionibacterium acnes wirksame Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Glycerinestern gesättigter Fettsäuren
EP3666259A1 (fr) Compositions aqueuses capables de mousser a base de biopolymeres avec une distribution de cellulures memoire de gas flexible selon son usage
DE102005008299A1 (de) Universalpflegecreme
WO2006122668A1 (fr) Combinaisons de matieres actives formees de glycerides de glucosyle et de creatine et/ou de creatinine
DE19618809C1 (de) Kosmetisches Mittel
WO2008046606A2 (fr) Composition topique pour le traitement d'eczéma
DE102006040450B3 (de) Verwendung einer Zusammensetzung für die Hautbehandlung nach Röntgenbestrahlung
WO2005034967A1 (fr) Composition pharmaceutique ou cosmetique pour traiter la peau
DE202016000224U1 (de) Wasser-in-Öl-Emulsion
WO2022248547A1 (fr) Compositions contenant des substances formant membrane pour la production d'une mousse formée par pompage
DE19625095C1 (de) Kosmetisches Mittel
EP3952822A1 (fr) Composition destinée à une application topique sur la peau
EP2683448B1 (fr) Mousse contenant un agent actif, un protéin et un ester d'un acide gras et procédé de préparation correspondante
DE202020005998U1 (de) Zuckerbasierte Enthaarungspaste
EP3746037A1 (fr) Pommade cicatrisante stable
DE102021000268A1 (de) Mineralölfreie kosmetische W/O-Emulsion
DE102012014688A1 (de) Chitosan-Präparat
DE102010015350A1 (de) Vaginalapplikator
DE102016009035A1 (de) Kosmetisches oder dermatologisches Mittel mit Paranussöl und Tapioca Stärke gegen trockene und schuppige Haut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1152874

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120615

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1152874

Country of ref document: HK